AI Support Tool to Help Dermatologists Diagnose Melanoma Skin Cancer
Tests whether an AI tool helps dermatologists judge if skin lesions are melanoma.
Plain-language title generated from the registry record
Registry title: Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis
Key facts
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, Stanford, and Uniondale, United StatesSee the 8 sites
- Phase
- Phase 3
Where in United States
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)Basking Ridge, United StatesTaking people
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)Commack, United StatesTaking people
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, United StatesTaking people
- Memorial Sloan Kettering Monmouth (Consent Only)Middletown, United StatesTaking people
- Memorial Sloan Kettering Bergen (Consent Only)Montvale, United StatesTaking people
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)New York, United StatesTaking people
- Stanford University (Data Collection Only)Stanford, United StatesNot yet recruiting
- Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)Uniondale, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT07890415
- Record updated
- 22 October 2026
- Original description
The purpose of this study is to learn whether a computer-based support tool called DEXI (Dermoscopy EXplainable Intelligence) can help dermatologists decide whether a lesion may be melanoma, a serious type of skin cancer. DEXI uses artificial intelligence, or AI, which means computer technology that looks for patterns in images and information. DEXI works within a software program called the DermaGraphix Visualizer, which displays and organizes skin and lesion images. The goal of this study is to see whether DEXI can help doctors find melanoma and reduce biopsies that may not be needed.Read full original descriptionShow less
Pragmatic Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) (AI)
The purpose of this study is to learn whether a computer-based support tool called DEXI (Dermoscopy EXplainable Intelligence) can help dermatologists decide whether a lesion may be melanoma, a serious type of skin cancer. DEXI uses artificial intelligence, or AI, which means computer technology that looks for patterns in images and information. DEXI works within a software program called the DermaGraphix Visualizer, which displays and organizes skin and lesion images. The goal of this study is to see whether DEXI can help doctors find melanoma and reduce biopsies that may not be needed.
Inclusion: Age 18 years or older at the time of scheduling the office visit; Presenting for an in-person office visit with an investigative provider at a participating clinical site during the study period. Both referral visits and recurring skin checks are eligible; Visit must have a mapped ICD-10 code with at least one of the following:; iii. C43 - Malignant melanoma of skin C44 - Other and unspecified malignant neoplasm of skin D03 - Melanoma in situ iv. D04 - Carcinoma in situ of skin v. D18.0 - Hemangioma vi. D22 - Melanocytic nevi vii. D23 - Other benign neoplasms of skin viii. D48.5 - Neoplasm of uncertain behavior of skin ix. D48.9 - - Neoplasm of uncertain behavior, unspecified x. D49.2 - Neoplasm of unspecified behavior of bone, soft tissue, and skin xi. I78.1 - Nevus, non-neoplastic xii. L57 - Skin changes due to chronic exposure to nonionizing radiation xiii. L73.8 - Other specified follicular disorders xiv. L81.4 - Other melanin hyperpigmentation xv. L82 - Seborrheic keratosis xvi. Q82.5 - Congenital non-neoplastic nevus xvii. Z12.83 - Encounter for screening for malignant neoplasm of skin xviii. Z80.8 - Family history of malignant neoplasm of other organs or systems xix. Z85.82 - Personal history of malignant neoplasm of skin xx. Z86.006 - Personal history of melanoma in-situ xxi. Z86.007 - Personal history of in-situ neoplasm of skin; Dermatologist conducting the visit must have undergone training for the how to use and interpret the CDS.
Exclusion: Telehealth-only, home, inpatient, emergency department, or procedure-only encounters without an in-office visit; If any image data captured on the patient were known to have been used for training or validating DEXI.